316 related articles for article (PubMed ID: 32553713)
1. Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.
Nicotera R; Casarella A; Longhitano E; Bolignano D; Andreucci M; De Sarro G; Cernaro V; Russo E; Coppolino G
Pharmacol Res; 2020 Sep; 159():105019. PubMed ID: 32553713
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
3. Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials.
Coppolino G; Leporini C; Rivoli L; Ursini F; di Paola ED; Cernaro V; Arturi F; Bolignano D; Russo E; De Sarro G; Andreucci M
Pharmacol Res; 2018 Mar; 129():274-294. PubMed ID: 29223646
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Liu WJ; Xie SH; Liu YN; Kim W; Jin HY; Park SK; Shao YM; Park TS
J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647
[TBL] [Abstract][Full Text] [Related]
5. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
Takashima S; Fujita H; Fujishima H; Shimizu T; Sato T; Morii T; Tsukiyama K; Narita T; Takahashi T; Drucker DJ; Seino Y; Yamada Y
Kidney Int; 2016 Oct; 90(4):783-96. PubMed ID: 27475229
[TBL] [Abstract][Full Text] [Related]
6. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
Tsuprykov O; Ando R; Reichetzeder C; von Websky K; Antonenko V; Sharkovska Y; Chaykovska L; Rahnenführer J; Hasan AA; Tammen H; Alter M; Klein T; Ueda S; Yamagishi SI; Okuda S; Hocher B
Kidney Int; 2016 May; 89(5):1049-1061. PubMed ID: 27083282
[TBL] [Abstract][Full Text] [Related]
7. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
Kanasaki K
Clin Sci (Lond); 2018 Feb; 132(4):489-507. PubMed ID: 29491123
[TBL] [Abstract][Full Text] [Related]
8. DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.
Abe M; Okada K
Contrib Nephrol; 2015; 185():98-115. PubMed ID: 26023019
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitors in progressive kidney disease.
Makino Y; Fujita Y; Haneda M
Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):67-73. PubMed ID: 25415611
[TBL] [Abstract][Full Text] [Related]
10. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.
Fujita H; Taniai H; Murayama H; Ohshiro H; Hayashi H; Sato S; Kikuchi N; Komatsu T; Komatsu K; Komatsu K; Narita T; Yamada Y
Endocr J; 2014; 61(2):159-66. PubMed ID: 24225429
[TBL] [Abstract][Full Text] [Related]
11. Physiology and pathophysiology of incretins in the kidney.
von Websky K; Reichetzeder C; Hocher B
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
Ayaori M; Iwakami N; Uto-Kondo H; Sato H; Sasaki M; Komatsu T; Iizuka M; Takiguchi S; Yakushiji E; Nakaya K; Yogo M; Ogura M; Takase B; Murakami T; Ikewaki K
J Am Heart Assoc; 2013 Jan; 2(1):e003277. PubMed ID: 23525426
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
15. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
[TBL] [Abstract][Full Text] [Related]
16. Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4.
Vallon V; Docherty NG
Exp Physiol; 2014 Sep; 99(9):1140-5. PubMed ID: 25085841
[TBL] [Abstract][Full Text] [Related]
17. Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease.
Davis H; Jones Briscoe V; Dumbadze S; Davis SN
Expert Opin Investig Drugs; 2019 Apr; 28(4):377-388. PubMed ID: 30848158
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes.
Duvnjak L; Perković MN; Blaslov K
J Diabetes Complications; 2017 Jan; 31(1):218-222. PubMed ID: 27625045
[TBL] [Abstract][Full Text] [Related]
19. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors.
Anderluh M; Kocic G; Tomovic K; Kocic R; Deljanin-Ilic M; Smelcerovic A
Pharmacol Ther; 2016 Nov; 167():100-107. PubMed ID: 27484974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]